开云app官网登录入口网页版-官方正版

#靶向新药#

12篇内容 | 935人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1932090, encodeId=170e193209066, content=<a href='/topic/show?id=f71299916ac' target=_blank style='color:#2F92EE;'>#靶向新药#</a>, objectTitle=PDGFRα靶向新药avapritinib在中国台湾申请用于治疗晚期胃肠道间质瘤成人患者, objectType=article, longId=191054, objectId=22d01910546b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=22d01910546b, replyNumber=0, likeNumber=108, createdTime=2020-07-28, rootId=0, userName=许安, userId=e2dd327, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=22d01910546b, moduleTitle=PDGFRα靶向新药avapritinib在中国台湾申请用于治疗晚期胃肠道间质瘤成人患者, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=22d01910546b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1932091, encodeId=057c1932091e0, content=<a href='/topic/show?id=f71299916ac' target=_blank style='color:#2F92EE;'>#靶向新药#</a>, objectTitle=全球第二个三代EGFR靶向新药阿美替尼上市, objectType=article, longId=193964, objectId=6d391939641c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6d391939641c, replyNumber=0, likeNumber=63, createdTime=2020-07-19, rootId=0, userName=许安, userId=e2dd327, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6d391939641c, moduleTitle=全球第二个三代EGFR靶向新药阿美替尼上市, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=6d391939641c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1932088, encodeId=aef1193208887, content=<a href='/topic/show?id=f71299916ac' target=_blank style='color:#2F92EE;'>#靶向新药#</a>, objectTitle=靶向新药仑伐替尼进入临床，专家共议肝癌多学科综合治疗新选择, objectType=article, longId=164618, objectId=644316461809, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=644316461809, replyNumber=0, likeNumber=81, createdTime=2019-10-04, rootId=0, userName=许安, userId=e2dd327, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=644316461809, moduleTitle=靶向新药仑伐替尼进入临床，专家共议肝癌多学科综合治疗新选择, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=644316461809)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1932086, encodeId=d4b5193208608, content=<a href='/topic/show?id=f71299916ac' target=_blank style='color:#2F92EE;'>#靶向新药#</a>, objectTitle=ASH大会盘点︱邱录贵教授：多发性骨髓瘤靶向新药与免疫治疗新近进展, objectType=article, longId=155535, objectId=1df5155535fc, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1df5155535fc, replyNumber=0, likeNumber=70, createdTime=2019-04-25, rootId=0, userName=许安, userId=e2dd327, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1df5155535fc, moduleTitle=ASH大会盘点︱邱录贵教授：多发性骨髓瘤靶向新药与免疫治疗新近进展, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=1df5155535fc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1932089, encodeId=29ee1932089cf, content=<a href='/topic/show?id=f71299916ac' target=_blank style='color:#2F92EE;'>#靶向新药#</a>, objectTitle=靶向新药百花齐放，NSCLC治疗和奥希替尼耐药后治疗应更个体化, objectType=article, longId=181299, objectId=64f618129957, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=64f618129957, replyNumber=0, likeNumber=77, createdTime=2020-09-05, rootId=0, userName=许安, userId=e2dd327, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=64f618129957, moduleTitle=靶向新药百花齐放，NSCLC治疗和奥希替尼耐药后治疗应更个体化, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=64f618129957)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1932087, encodeId=7fcb193208ef2, content=<a href='/topic/show?id=f71299916ac' target=_blank style='color:#2F92EE;'>#靶向新药#</a>, objectTitle=Biomaterials：沈华浩团队发现纳米药物有望成为治疗哮喘的潜在靶向新药, objectType=article, longId=156397, objectId=025f15639e9b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=025f15639e9b, replyNumber=0, likeNumber=76, createdTime=2019-08-18, rootId=0, userName=许安, userId=e2dd327, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=025f15639e9b, moduleTitle=Biomaterials：沈华浩团队发现纳米药物有望成为治疗哮喘的潜在靶向新药, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=025f15639e9b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1932085, encodeId=a3401932085c9, content=<a href='/topic/show?id=f71299916ac' target=_blank style='color:#2F92EE;'>#靶向新药#</a>, objectTitle=全球用于治疗BRAFV600突变阳性的无法手术切除或转移性黑色素瘤的靶向新药佐博伏® 中国上市 CFDA审评概述, objectType=article, longId=122007, objectId=8d8a12200e1b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8d8a12200e1b, replyNumber=0, likeNumber=78, createdTime=2018-09-26, rootId=0, userName=许安, userId=e2dd327, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8d8a12200e1b, moduleTitle=全球用于治疗BRAFV600突变阳性的无法手术切除或转移性黑色素瘤的靶向新药佐博伏® 中国上市 CFDA审评概述, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=8d8a12200e1b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1932083, encodeId=3d65193208313, content=<a href='/topic/show?id=f71299916ac' target=_blank style='color:#2F92EE;'>#靶向新药#</a>, objectTitle=“癌王”黑色素瘤靶向新药佐博伏(R)在中国上市, objectType=article, longId=107270, objectId=d93d10e27084, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d93d10e27084, replyNumber=0, likeNumber=65, createdTime=2017-10-28, rootId=0, userName=许安, userId=e2dd327, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d93d10e27084, moduleTitle=“癌王”黑色素瘤靶向新药佐博伏(R)在中国上市, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=d93d10e27084)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1932082, encodeId=d86819320820d, content=<a href='/topic/show?id=f71299916ac' target=_blank style='color:#2F92EE;'>#靶向新药#</a>, objectTitle=ASCO2017：尤文肉瘤靶向新药物TK216 I期临床试验开展, objectType=article, longId=101269, objectId=286810126909, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=286810126909, replyNumber=0, likeNumber=111, createdTime=2017-10-15, rootId=0, userName=许安, userId=e2dd327, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=286810126909, moduleTitle=ASCO2017：尤文肉瘤靶向新药物TK216 I期临床试验开展, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=286810126909)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1932084, encodeId=ee951932084c7, content=<a href='/topic/show?id=f71299916ac' target=_blank style='color:#2F92EE;'>#靶向新药#</a>, objectTitle=靶向新药伊布替尼获批新适应症——复发难治性边缘区淋巴瘤（MZL）, objectType=article, longId=116548, objectId=8f8f1165488a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8f8f1165488a, replyNumber=0, likeNumber=79, createdTime=2018-04-22, rootId=0, userName=许安, userId=e2dd327, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8f8f1165488a, moduleTitle=靶向新药伊布替尼获批新适应症——复发难治性边缘区淋巴瘤（MZL）, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=8f8f1165488a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1932081, encodeId=a63a193208167, content=<a href='/topic/show?id=f71299916ac' target=_blank style='color:#2F92EE;'>#靶向新药#</a>, objectTitle=FDA批准急性髓性白血病（AML）靶向新药midostaurin, objectType=article, longId=97666, objectId=cf8a9e666c6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cf8a9e666c6, replyNumber=0, likeNumber=69, createdTime=2017-12-09, rootId=0, userName=许安, userId=e2dd327, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cf8a9e666c6, moduleTitle=FDA批准急性髓性白血病（AML）靶向新药midostaurin, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=cf8a9e666c6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1932080, encodeId=6516193208010, content=<a href='/topic/show?id=f71299916ac' target=_blank style='color:#2F92EE;'>#靶向新药#</a>, objectTitle=Clin Cancer Res：PI3K靶向新药Pictilisib在进展期实体肿瘤病人中的I期临床试验, objectType=article, longId=42400, objectId=3e374240092, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3e374240092, replyNumber=0, likeNumber=0, createdTime=2015-04-03, rootId=0, userName=许安, userId=e2dd327, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3e374240092, moduleTitle=Clin Cancer Res：PI3K靶向新药Pictilisib在进展期实体肿瘤病人中的I期临床试验, moduleType=article, hrefUrl=//m.sandwebs.com/article/show_article.do?id=3e374240092)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 风湿免疫小助手

靶向新药

2020-05-29

许安 (审核中...)

前往app查看评论内容

#靶向新药#

PDGFRα靶向新药avapritinib在中国台湾申请用于治疗晚期胃肠道间质瘤成人患者

2020-07-28

许安 (审核中...)

前往app查看评论内容

#靶向新药#

全球第二个三代EGFR靶向新药阿美替尼上市

2020-07-19

许安 (审核中...)

前往app查看评论内容

#靶向新药#

靶向新药仑伐替尼进入临床，专家共议肝癌多学科综合治疗新选择

2019-10-04

许安 (审核中...)

前往app查看评论内容

#靶向新药#

ASH大会盘点︱邱录贵教授：多发性骨髓瘤靶向新药与免疫治疗新近进展

2019-04-25

许安 (审核中...)

前往app查看评论内容

#靶向新药#

靶向新药百花齐放，NSCLC治疗和奥希替尼耐药后治疗应更个体化

2020-09-05

许安 (审核中...)

前往app查看评论内容

#靶向新药#

Biomaterials：沈华浩团队发现纳米药物有望成为治疗哮喘的潜在靶向新药

2019-08-18

许安 (审核中...)

前往app查看评论内容

#靶向新药#

全球用于治疗BRAFV600突变阳性的无法手术切除或转移性黑色素瘤的靶向新药佐博伏® 中国上市 CFDA审评概述

2018-09-26

许安 (审核中...)

前往app查看评论内容

#靶向新药#

“癌王”黑色素瘤靶向新药佐博伏(R)在中国上市

2017-10-28

许安 (审核中...)

前往app查看评论内容

#靶向新药#

ASCO2017：尤文肉瘤靶向新药物TK216 I期临床试验开展

2017-10-15

许安 (审核中...)

前往app查看评论内容

#靶向新药#

靶向新药伊布替尼获批新适应症——复发难治性边缘区淋巴瘤（MZL）

2018-04-22

许安 (审核中...)

前往app查看评论内容

#靶向新药#

FDA批准急性髓性白血病（AML）靶向新药midostaurin

2017-12-09

许安 (审核中...)

前往app查看评论内容

#靶向新药#

Clin Cancer Res：PI3K靶向新药Pictilisib在进展期实体肿瘤病人中的I期临床试验

2015-04-03

科室
- - 订阅+
  - 更多科室
工具
服务